<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70502">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01915641</url>
  </required_header>
  <id_info>
    <org_study_id>101-5303B</org_study_id>
    <nct_id>NCT01915641</nct_id>
  </id_info>
  <brief_title>CPAP Improves the Walking Capacity in Patients With COPD and OSA</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have reported that CPAP treatment improved the walking capacity of overlap syndrome
      patients.

      However, the previous study was not randomized, double blinded study. Therefore, we design a
      prospective, randomized, double blinded, controlled, cross-over trial to confirm this
      finding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      inclusion criteria :

        -  COPD : FEV1/FVC &lt; 70%, no response to bronchodilator (FEV1 change &lt;12% and &lt;200ml)

        -  OSA : AHI &gt; 15/h, obstructive type predominant

      exclusion criteria :

        -  any malignancy

        -  pregnancy

        -  claustrophobia

        -  age&lt;18

      primary outcome : exercise capacity (walking distance (meter), measured by incremental
      shuttle walking test)

      Method : For those fit in criteria. CPAP titration will be performed to determine the
      optimal pressure Baseline measurement : incremental shuttle walking test, urine
      catecholamine, heart rate variability, muscle power and other baseline characteristics
      Randomized those patients to group A and group B group A : CPAP treatment with optimal
      pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for
      1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat
      measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>exercise capacity (walking distance (meter), measured by incremental shuttle walking test)</measure>
    <time_frame>CPAP treatment for 1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Walking Capacity</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
    <other_name>continuous positive airway pressure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FEV1/FVC &lt; 70%, no response to bronchodilator (FEV1 change &lt;12% and &lt;200ml)

          -  OSA : AHI &gt; 15/h, obstructive type predominant

        Exclusion Criteria:

          -  any malignancy

          -  pregnancy

          -  claustrophobia

          -  age&lt;18
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TSAI-YU WANG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Thoracic Medicine, Chang Gung Memorial Hospital 199 Tun-Hwa N. Rd., Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>TSAI-YU WANG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Thoracic Medicine, Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>TSAI-YU WANG, MD</last_name>
    <phone>(886) 3-328-1200</phone>
    <phone_ext>8467</phone_ext>
    <email>wang5531@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Thoracic Medicine, Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TSAI-YU WANG, MD</last_name>
      <phone>886975368076</phone>
      <email>wang5531@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>August 2, 2013</lastchanged_date>
  <firstreceived_date>July 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>walking capacity</keyword>
  <keyword>COPD</keyword>
  <keyword>OSA</keyword>
  <keyword>CPAP</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
